1 / 25

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer. Presented By Boris Winterhoff at 2014 ASCO Annual Meeting. Disclosure. Presented By Boris Winterhoff at 2014 ASCO Annual Meeting. Slide 3.

illias
Télécharger la présentation

Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

  2. Disclosure Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

  3. Slide 3 Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

  4. ICON7/AGO-OVAR 11 Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

  5. ICON7/AGO-OVAR 11 <br />PFS and OS Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

  6. ICON7/AGO-OVAR 11 <br />PFS and OS<br />High risk group suboptimal stage III and stage IV Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

  7. Molecular Classification of HGS Ovarian Cancer Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

  8. Slide 8 Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

  9. Slide 9 Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

  10. Slide 10 Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

  11. Slide 11 Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

  12. Slide 12 Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

  13. PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort<br />Overall (n=359) Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

  14. PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort<br />High risk for progression (n=119) Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

  15. PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort<br />Proliferative Subtype (n=96) Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

  16. PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort<br />Mesenchymal Subtype (n=68) Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

  17. PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort<br />Differentiated Subtype (n=73) Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

  18. PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort<br />Immunoreactive Subtype (n=122) Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

  19. Slide 19 Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

  20. PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort<br />Proliferative Subtype HGS (n=63) Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

  21. PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort<br />Mesenchymal Subtype HGS (n=43) Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

  22. Summary Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

  23. Conclusion Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

  24. Acknowledgements Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

  25. Summary Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

More Related